Biocept (Biocept) COGS-to-Revenue

: 4.33 (As of Jun. 2023)

View and export this data going back to 2014. Start your Free Trial

Biocept's Cost of Goods Sold for the three months ended in Jun. 2023 was $2.55 Mil. Its Revenue for the three months ended in Jun. 2023 was $0.59 Mil.

Biocept's COGS to Revenue for the three months ended in Jun. 2023 was 4.33.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Biocept's Gross Margin % for the three months ended in Jun. 2023 was -332.94%.

Biocept COGS-to-Revenue Historical Data

The historical data trend for Biocept's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocept Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

COGS-to-Revenue

3.09

1.99

0.78

0.62

1.10

Biocept Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
COGS-to-Revenue																1.38	5.74	-	4.50	4.33

Biocept COGS-to-Revenue Calculation

Biocept's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	28.44	/	25.858
	=	1.10

Biocept's COGS to Revenue for the quarter that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2.55	/	0.589
	=	4.33

Biocept (OTCPK:BIOCQ) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Biocept's Gross Margin % for the three months ended in Jun. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	2.55 / 0.589
	=	-332.94 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Biocept COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biocept's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocept (Biocept) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (OTCPK:BIOCQ) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

9955 Mesa Rim Road, San Diego, CA, USA, 92121

Website

https://www.biocept.com

Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Executives

Robert Walsh	officer: VP, Controller	9955 MESA RIM ROAD, SAN DIEGO CA 92121
Quyen Thi Dao-haddock	director	C/O: PRESIDIO PROPERTY TRUST, INC., 1282 PACIFIC OAKS PLACE, ESCONDIDO CA 92029
Philippe Marchand	officer: Chief Operations Officer	C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Darrell Taylor	officer: Sr. V.P., General Counsel	C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
David F Hale	director, officer: EXECUTIVE CHAIRMAN	1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Antonino Morales	director	C/O BICOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Linda M Rubinstein	director	25861 INDUSTRIAL BLVD, HAYWARD CA 94545
Samuel D Riccitelli	director	2850 FRONTIER DR., WARSAW IN 46582
Michael C Dugan	officer: Chief Med Off & Med. Director	2211 MICHIGAN AVE, SANTA MONICA CA 90404-3900
Dunn Cory	officer: Sr. VP Corp. Development	C/O BIOCEPT, INC., 5810 NANCY RIDGE DR., # 150, SAN DIEGO CA 92121
Edwin Hendrick	officer: SVP, Chief Commercial Officer	2010 MAIN STREET, SUITE 600, IRVINE CA 92614
Michael J Terry	officer: Sr VP Comm. Operations
Marsha Alpert Chandler	director	7863 ENTRADA ANGELICA, SAN DIEGO CA 92127
Michael W. Nall	director, officer: CEO AND PRESIDENT	4 WOODHAVEN DRIVE, LAGUNA NIGUEL CA 92677
Timothy Kennedy	officer: CFO, Sr V.P. Operations & Sec.	5810 NANCY RIDGE DRIVE, SUITE 150, SAN DIEGO CA 92121